Fidaxomicin/Dificlir Mode-of-Action
Tillotts Pharma reached out to us to create a Mode-of-Action video explaining what C. difficle infection (CDI) is, the significant challenges it presents and the benefits of tackling it with a targeted antibacterial agent such as Dificlir (fidaxomicin) as opposed to a broad spectrum antibiotic. Key to the presentation was conveying the paradox where broad spectrum antibiotic use for CDI not only harms the C. difficile bacteria but also harms the native microbiota which can increase the chance of CDI recurrence.
The presentation starts with the lifecycle of C. difficile from its injestion in spore form and germination in the small intestine to its subsequent passing into the colon. This section also highlighted that a healthy competitive microbiota in the colon actively suppresses C. difficle colonization.
The disruption to the microbiota caused by broad spectrum antibiotic use and the subsequent colonization by C. difficile was made to be very visual - giving a real sense of the overgrowth of C. difficile and the damage to the native microbiota.
The core mechanism-of-action of the fidaxomicin was covered by showing fidaxomicin binding to a specific residue on the C. difficile RNA polymerase and thereby preventing transcription and blocking protein synthesis.
The presentation draws to a close showing the destruction of a C. difficle colonization by Dificlir whilst preserving the natural biome - avoiding the earlier explained paradox. Dificlir's other benefit, inhibition of C. difficile's toxin mediated inflammatory response and tissue damage in the colon was also shown.
Fidaxomicin/Dificlir Mode-of-Action
Full Presentation
It was requested that the presentation work with or without sound and on smaller screens, so larger labels were employed and subtitles were added.
